2016
Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment.
Kim J, Kang Y, Shin M, Deshpande H, Hurwitz M, Roberts J, Cardinale J, Narayana A, Kang I, Petrylak D. Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. Journal Of Clinical Oncology 2016, 34: 295-295. DOI: 10.1200/jco.2016.34.2_suppl.295.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPeripheral blood mononuclear cellsT cell immunityT cellsCell immunityOsseous metastasesMetastatic castration-resistant prostateCastration-resistant prostate cancerIL-7 receptor alpha chainRadium-223 treatmentEffector memory CD8PD-1 expressionEffector T cellsDeath protein 1Resistant prostate cancerCastration-resistant prostateBlood mononuclear cellsFollowing time pointsCocktail of antibodiesHost immune systemReceptor alpha chainCalcium mimeticEligible patientsEM CD8Median PSA
2015
Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014.
Flaig T, Tangen C, Hussain M, Agarwal N, Mitsiades N, Deshpande H, Vaishampayan U, Thompson I. Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. Journal Of Clinical Oncology 2015, 33: 152-152. DOI: 10.1200/jco.2015.33.7_suppl.152.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalMonths of ADTInitial androgen deprivation therapyTime of enrollmentDeprivation therapyPSA responsePoor prognosisGrade 3 adverse eventsMedian progression-free survivalMetastatic prostate cancer patientsAbiraterone acetate treatmentMetastatic PC patientsSecondary hormonal therapySubsequent median survivalPhase II trialProstate cancer patientsEligible patientsUndetectable PSAALT elevationEfficacy of AAHormonal therapyII trialPrimary endpointRectal bleeding